Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (Anadur) for male fertility regulation.
To test the effectiveness of 19-nortestosterone (19NT) as an antifertility agent, 12 normal men (age, 24.0 +/- 2.2 years) received 19NT-hexoxyphenylpropionate (19NT-HPP), 200 mg/week intramuscularly for 7 weeks. After this initial phase, two groups were formed that received injections at different intervals. Except for the 19NT serum levels, there was no difference in treatment effects between both groups. 19NT-HPP administration in general suppressed gonadotropins below detection limits, accompanied by testosterone levels well in the castrate range. At the end of the treatment phase, azoospermia or severe oligozoospermia (total sperm count less than 5 X 10(6)) was present in ten volunteers. No loss of libido or potency was reported. Administration of 19NT-HPP did not affect liver enzymes, creatinine, uric acid, serum electrolytes, or serum lipids. The presented data demonstrate that 19NT-HPP as a single entity given every 3 weeks can suppress sperm output in a high proportion of men and simultaneously maintain virility.
D000328:Adult; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003272:Contraceptive Agents, Male; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D013076:Sperm Count; D013081:Sperm Motility; D013739:Testosterone / Q000097:blood
D003272:Contraceptive Agents, Male; D013739:Testosterone; C034345:19-nortestosterone 4-hexoxyphenylpropionate; D009277:Nandrolone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone